These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 27354684)

  • 1. The effectiveness of a real life dose reduction strategy for tumour necrosis factor inhibitors in ankylosing spondylitis and psoriatic arthritis.
    Fong W; Holroyd C; Davidson B; Armstrong R; Harvey N; Dennison E; Cooper C; Edwards CJ
    Rheumatology (Oxford); 2016 Oct; 55(10):1837-42. PubMed ID: 27354684
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk of active tuberculosis in patients with inflammatory arthritis receiving TNF inhibitors: a look beyond the baseline tuberculosis screening protocol.
    Soare A; Gheorghiu AM; Aramă V; Bumbăcea D; Dobrotă R; Oneaţă R; Pintilie S; Milicescu M; Ancuţa I; Martin A; Sasu M; Ciofu C; Macovei L; Stoica V; Bojincă M; Mihai C
    Clin Rheumatol; 2018 Sep; 37(9):2391-2397. PubMed ID: 29150737
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumour necrosis factor inhibitor dose adaptation in psoriatic arthritis and axial spondyloarthritis (TAPAS): a retrospective cohort study.
    Michielsens CAJ; den Broeder N; Mulder MLM; van den Hoogen FHJ; Verhoef LM; den Broeder AA
    Rheumatology (Oxford); 2022 May; 61(6):2307-2315. PubMed ID: 34599803
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of extra-articular manifestations on tumor necrosis factor-α inhibitor treatment duration in patients with ankylosing spondylitis: nationwide data from the Korean College of Rheumatology BIOlogics (KOBIO) registry.
    Kim Y; Park S; Kim HS
    Clin Rheumatol; 2018 Dec; 37(12):3275-3284. PubMed ID: 30251059
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cancer risk in patients with spondyloarthritis treated with TNF inhibitors: a collaborative study from the ARTIS and DANBIO registers.
    Hellgren K; Dreyer L; Arkema EV; Glintborg B; Jacobsson LT; Kristensen LE; Feltelius N; Hetland ML; Askling J;
    Ann Rheum Dis; 2017 Jan; 76(1):105-111. PubMed ID: 27147709
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-life 10-year retention rate of first-line anti-TNF drugs for inflammatory arthritides in adult- and juvenile-onset populations: similarities and differences.
    Favalli EG; Pontikaki I; Becciolini A; Biggioggero M; Ughi N; Romano M; Crotti C; Gattinara M; Gerloni V; Marchesoni A; Meroni PL
    Clin Rheumatol; 2017 Aug; 36(8):1747-1755. PubMed ID: 28597133
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The use of adalimumab, etanercept, golimumab and infliximab in rheumatic pathologies: variation between label dosage and real-world use.
    Martinez-Cutillas J; Alerany-Pardo C; Borrás-Blasco J; Broto-Sumalla A; Burgos-SanJosé A; Climent-Bolta C; Escudero-Vilaplana V; Fernández-Fuente MA; Ferrit-Martin M; Gómez-Germá P; Martínez-Sesmero JM; Mayorga-Pérez J; Menchén-Viso B; Merino-Alonso J; Polache-Vengud J; Sánchez-Guerrero A
    Expert Rev Pharmacoecon Outcomes Res; 2015; 15(5):851-8. PubMed ID: 25972066
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumour necrosis factor inhibitor survival and predictors of response in axial spondyloarthritis-findings from a United Kingdom cohort.
    Yahya F; Gaffney K; Hamilton L; Lonsdale E; Leeder J; Brooksby A; Cavill C; Berry-Jenkins J; Boyle C; Bond D; Sengupta R;
    Rheumatology (Oxford); 2018 Apr; 57(4):619-624. PubMed ID: 29272541
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness and safety of adalimumab in patients with ankylosing spondylitis or psoriatic arthritis and history of anti-tumor necrosis factor therapy.
    Rudwaleit M; Van den Bosch F; Kron M; Kary S; Kupper H
    Arthritis Res Ther; 2010; 12(3):R117. PubMed ID: 20553600
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Switching between TNF inhibitors in psoriatic arthritis: data from the NOR-DMARD study.
    Fagerli KM; Lie E; van der Heijde D; Heiberg MS; Kalstad S; Rødevand E; Mikkelsen K; Lexberg AS; Kvien TK
    Ann Rheum Dis; 2013 Nov; 72(11):1840-4. PubMed ID: 23562987
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative Persistence of Methotrexate and Tumor Necrosis Factor Inhibitors in Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis.
    George MD; Baker JF; Ogdie A
    J Rheumatol; 2020 Jun; 47(6):826-834. PubMed ID: 31474599
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impaired response to treatment with tumour necrosis factor α inhibitors in smokers with axial spondyloarthritis.
    Ciurea A; Scherer A; Weber U; Exer P; Bernhard J; Tamborrini G; Riek M; Müller RB; Weiss B; Nissen MJ; Kissling R; Michel BA; Finckh A;
    Ann Rheum Dis; 2016 Mar; 75(3):532-9. PubMed ID: 25667205
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Disease Activity Cutoff Values in Initiating Tumor Necrosis Factor Inhibitor Therapy in Ankylosing Spondylitis: A German GO-NICE Study Subanalysis.
    Braun J; Baraliakos X; Kiltz U; Krüger K; Burmester GR; Wassenberg S; Thomas MH
    J Rheumatol; 2020 Jan; 47(1):35-41. PubMed ID: 30877206
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The influence of obesity on response to tumour necrosis factor-α inhibitors in psoriatic arthritis: results from the DANBIO and ICEBIO registries.
    Højgaard P; Glintborg B; Kristensen LE; Gudbjornsson B; Love TJ; Dreyer L
    Rheumatology (Oxford); 2016 Dec; 55(12):2191-2199. PubMed ID: 27651526
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of tumor necrosis factor-alpha inhibitors during pregnancy among women who delivered live born infants.
    Eworuke E; Panucci G; Goulding M; Neuner R; Toh S
    Pharmacoepidemiol Drug Saf; 2019 Mar; 28(3):296-304. PubMed ID: 30430682
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment persistence among patients with immune-mediated rheumatic disease newly treated with subcutaneous TNF-alpha inhibitors and costs associated with non-persistence.
    Dalén J; Svedbom A; Black CM; Lyu R; Ding Q; Sajjan S; Sazonov V; Kachroo S
    Rheumatol Int; 2016 Jul; 36(7):987-95. PubMed ID: 26780533
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identifying inadequate response among patients with ankylosing spondylitis and psoriatic arthritis prescribed advanced therapy in a real-world, commercially insured adult population in the USA.
    Hunter T; Grabner M; Birt J; Isenberg K; Shan M; Teng CC; Wu J; Griffing K; Lisse J; Curtis JR
    Clin Rheumatol; 2022 Sep; 41(9):2863-2874. PubMed ID: 35672618
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative Efficacy of Tumor Necrosis Factor-α Inhibitors in Ankylosing Spondylitis: A Systematic Review and Bayesian Network Metaanalysis.
    Wang R; Dasgupta A; Ward MM
    J Rheumatol; 2018 Apr; 45(4):481-490. PubMed ID: 29335342
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative Analysis and Predictors of 10-year Tumor Necrosis Factor Inhibitors Drug Survival in Patients with Spondyloarthritis: First-year Response Predicts Longterm Drug Persistence.
    Flouri ID; Markatseli TE; Boki KA; Papadopoulos I; Skopouli FN; Voulgari PV; Settas L; Zisopoulos D; Iliopoulos A; Geborek P; Drosos AA; Boumpas DT; Sidiropoulos P
    J Rheumatol; 2018 Jun; 45(6):785-794. PubMed ID: 29606666
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Maternal and Fetal Outcomes in a Cohort of Patients Exposed to Tumor Necrosis Factor Inhibitors throughout Pregnancy.
    Genest G; Spitzer KA; Laskin CA
    J Rheumatol; 2018 Aug; 45(8):1109-1115. PubMed ID: 29961692
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.